Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
Recruiting · NCT06607276 · Registry updated 2025-01-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2025-01-16 | NCT06607276 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jinling Hospital, China | 33 |
| The First Affiliated Hospital with Nanjing Medical University | 319 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Jinling Hospital | Nanjing | China | 1 |
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou | China | 1 |
| The First Affiliated Hospital of Nanjing Medical University | Nanjing | China | 2 |
| Yancheng NO.1 People's Hospital | Yancheng | China | 1 |